Mets E, Van der Meulen J, Van Peer G, Boice M, Mestdagh P, Van de Walle I, Lammens T, Goossens S, De Moerloose B, Benoit Y, Van Roy N, Clappier E, Poppe B, Vandesompele J, Wendel H-G, Taghon T, Rondou P, Soulier J, Van Vlierberghe P, Speleman F
Center for Medical Genetics, Ghent University, Ghent, Belgium.
Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Leukemia. 2015 Apr;29(4):798-806. doi: 10.1038/leu.2014.276. Epub 2014 Sep 18.
The MYB oncogene is a leucine zipper transcription factor essential for normal and malignant hematopoiesis. In T-cell acute lymphoblastic leukemia (T-ALL), elevated MYB levels can arise directly through T-cell receptor-mediated MYB translocations, genomic MYB duplications or enhanced TAL1 complex binding at the MYB locus or indirectly through the TAL1/miR-223/FBXW7 regulatory axis. In this study, we used an unbiased MYB 3'untranslated region-microRNA (miRNA) library screen and identified 33 putative MYB-targeting miRNAs. Subsequently, transcriptome data from two independent T-ALL cohorts and different subsets of normal T-cells were used to select miRNAs with relevance in the context of normal and malignant T-cell transformation. Hereby, miR-193b-3p was identified as a novel bona fide tumor-suppressor miRNA that targets MYB during malignant T-cell transformation thereby offering an entry point for efficient MYB targeting-oriented therapies for human T-ALL.
MYB癌基因是一种亮氨酸拉链转录因子,对正常和恶性造血至关重要。在T细胞急性淋巴细胞白血病(T-ALL)中,MYB水平升高可直接通过T细胞受体介导的MYB易位、基因组MYB重复或TAL1复合物在MYB基因座处的结合增强而发生,或间接通过TAL1/miR-223/FBXW7调节轴发生。在本研究中,我们使用了一个无偏向性的MYB 3'非翻译区-微小RNA(miRNA)文库筛选,并鉴定出33个假定的靶向MYB的miRNA。随后,来自两个独立T-ALL队列和不同正常T细胞亚群的转录组数据被用于选择在正常和恶性T细胞转化背景下相关的miRNA。据此,miR-193b-3p被鉴定为一种新型的真正的肿瘤抑制miRNA,它在恶性T细胞转化过程中靶向MYB,从而为人类T-ALL的高效靶向MYB治疗提供了一个切入点。